CareDx Inc
CDNA19.470USD
+1.120+6.10%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
1.00BMarktkapitalisierung
14.43KGV TTM
mehr Informationen über CareDx Inc Unternehmen
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
CareDx Inc Informationen
BörsenkürzelCDNA
Name des UnternehmensCareDx Inc
IPO-datumJul 17, 2014
CEOHanna (John W)
Anzahl der mitarbeiter644
WertpapierartOrdinary Share
GeschäftsjahresendeJul 17
Addresse8000 Marina Blvd
StadtBRISBANE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94005
Telefon14152872300
Websitehttps://www.caredx.com/
BörsenkürzelCDNA
IPO-datumJul 17, 2014
CEOHanna (John W)
Führungskräfte von CareDx Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-10000.00%
Ms. Jessica Meng
Ms. Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
176.78K
+67149.00%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
146.89K
+1492.00%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+12103.00%
Mr. Nathan Smith
Mr. Nathan Smith
Chief Financial Officer
Chief Financial Officer
79.02K
+37016.00%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Ms. Christine M. Cournoyer
Ms. Christine M. Cournoyer
Independent Director
Independent Director
38.58K
+12103.00%
Mr. Jeffrey Adam Novack
Mr. Jeffrey Adam Novack
General Counsel, Secretary
General Counsel, Secretary
37.63K
+27439.00%
Mr. Suresh Gunasekaran
Mr. Suresh Gunasekaran
Director
Director
27.45K
+27453.00%
Mr. George W. Bickerstaff, III
Mr. George W. Bickerstaff, III
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-10000.00%
Ms. Jessica Meng
Ms. Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
176.78K
+67149.00%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
146.89K
+1492.00%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+12103.00%
Mr. Nathan Smith
Mr. Nathan Smith
Chief Financial Officer
Chief Financial Officer
79.02K
+37016.00%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Umsatzaufteilung
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Testing Service revenue
72.17M
0.00%
Digital and other revenue
15.41M
0.00%
Product revenue
12.48M
0.00%
Nach RegionUSD
Name
Umsatz
Anteil
United States
95.06M
0.00%
Rest of the world
5.00M
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Testing Service revenue
72.17M
0.00%
Digital and other revenue
15.41M
0.00%
Product revenue
12.48M
0.00%
Aktionärsstatistik
Aktualisiert: Mon, Nov 17
Aktualisiert: Mon, Nov 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
8.01%
The Vanguard Group, Inc.
6.64%
Baron Capital Management, Inc.
6.13%
State Street Investment Management (US)
4.99%
Ophir Asset Management Pty Ltd
4.27%
Andere
69.95%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
8.01%
The Vanguard Group, Inc.
6.64%
Baron Capital Management, Inc.
6.13%
State Street Investment Management (US)
4.99%
Ophir Asset Management Pty Ltd
4.27%
Andere
69.95%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
41.70%
Investment Advisor
35.07%
Hedge Fund
21.15%
Individual Investor
4.50%
Research Firm
3.27%
Pension Fund
0.56%
Bank and Trust
0.41%
Insurance Company
0.03%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
443
52.64M
115.22%
+43.46K
2025Q3
457
52.61M
115.96%
-1.80M
2025Q2
454
53.72M
112.39%
-1.85M
2025Q1
443
55.89M
106.19%
-3.01M
2024Q4
439
52.97M
108.30%
+1.05M
2024Q3
434
51.58M
120.50%
-825.62K
2024Q2
407
52.51M
127.45%
-1.22M
2024Q1
435
53.86M
132.45%
-14.73M
2023Q4
448
52.78M
128.80%
-2.04M
2023Q3
476
54.42M
142.26%
-1.69M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
4.12M
8.01%
+53.87K
+1.33%
Sep 30, 2025
The Vanguard Group, Inc.
3.74M
7.27%
-1.16M
-23.69%
Sep 30, 2025
Baron Capital Management, Inc.
3.16M
6.13%
+719.52K
+29.54%
Sep 30, 2025
State Street Investment Management (US)
2.57M
4.99%
+386.30K
+17.72%
Sep 30, 2025
Ophir Asset Management Pty Ltd
2.20M
4.27%
+304.95K
+16.11%
Sep 30, 2025
Deerfield Management Company, L.P.
2.19M
4.26%
+2.19M
--
Sep 30, 2025
Braidwell LP
2.18M
4.24%
+2.18M
--
Sep 30, 2025
ARK Investment Management LLC
2.17M
4.22%
+70.47K
+3.36%
Sep 30, 2025
Gagnon Securities LLC
1.73M
3.36%
-404.70K
-18.96%
Sep 30, 2025
Amova Asset Management Co., Ltd.
1.74M
3.38%
+503.14K
+40.68%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
ARK Genomic Revolution ETF
2.89%
ROBO Global Healthcare Technology & Innovation ETF
1.93%
Global X Genomics & Biotechnology ETF
0.87%
Franklin Genomic Advancements ETF
0.72%
State Street SPDR S&P Biotech ETF
0.34%
Direxion Daily S&P Biotech Bull 3X Shares
0.21%
iShares Micro-Cap ETF
0.16%
Fidelity Enhanced Small Cap ETF
0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.11%
Principal U.S. Small-Cap ETF
0.1%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil2.89%
ROBO Global Healthcare Technology & Innovation ETF
Anteil1.93%
Global X Genomics & Biotechnology ETF
Anteil0.87%
Franklin Genomic Advancements ETF
Anteil0.72%
State Street SPDR S&P Biotech ETF
Anteil0.34%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.21%
iShares Micro-Cap ETF
Anteil0.16%
Fidelity Enhanced Small Cap ETF
Anteil0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.11%
Principal U.S. Small-Cap ETF
Anteil0.1%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
